As the only molecule that can transport iron to the cell exterior,the ferroportin 1(FPN1)plays a key role in regulating the homeostasis of the iron ion.However,the function of FPN1 in teleost is remains unclear.In thi...As the only molecule that can transport iron to the cell exterior,the ferroportin 1(FPN1)plays a key role in regulating the homeostasis of the iron ion.However,the function of FPN1 in teleost is remains unclear.In this study,the fpn1 gene was cloned from grass carp and its characteristics were studied.The results showed that grass carp Fpn1 protein contains eight transmembrane domains,which are similar to the amino acid sequences of different species.The tissue distribution of fpn1 was investigated by quantitative real-time PCR(qRT-PCR),which showed that the expression of fpn1 was the highest in the liver,followed by the spleen and muscle.Secondly,the haemolysis model of grass carp was established by the injection of phenylhydrazine(PHZ),and the effect of Fpn1 on the intestine in during haemolysis was explored.The determination data revealed that the PHZ-induced haemolysis increased the number of goblet cells in intestinal,as well as malondialdehyde(Mda),decreased glutathione peroxidase 4(Gpx4)content in foregut.The result of tissue immunofluorescence assay showed that the PHZ-induced haemolysis modulated the expression of iron metabolism related genes,including Fpn1 and Tfr1(transferrin receptor 1)in the intestine.Further determination data suggested that the iron deposition and apoptosis were higher in PHZ treatment group than that of the group.Taken together,the PHZ-induced haemolysis destroyed the iron homeostasis in intestinal and caused oxidative damage,the data of this study lays a foundation for the study of the mechanisms of intestinal iron homeostasis and provides a theoretical basis for understanding intestinal healthy.展开更多
Aim:To determine the tolerance and acceptance of hepatic venous pressure gradient(HVPG)measurements in patients with liver cirrhosis.Methods:This prospective international multicenter study included 271 patients with ...Aim:To determine the tolerance and acceptance of hepatic venous pressure gradient(HVPG)measurements in patients with liver cirrhosis.Methods:This prospective international multicenter study included 271 patients with cirrhosis who were scheduled to undergo HVPG measurement between October 2019 and June 2020.Data related to the tolerance and acceptance of HVPG measurements were collected using descriptive questionnaires.Results:HVPG measurements were technically successful in all 271 patients,with 141(52.0%)undergoing HVPG measurement alone.The complication rate was 0.4%.Postoperative pain was significantly lower than preoperative expected pain(p<0.001)and intraoperative pain(p<0.001),and intraoperative pain was also significantly lower than preoperative expected pain(p=0.036).No,mild,moderate,severe,and intolerable discomfort scores were reported by 36.9%,44.6%,11.1%,6.3%,and 0.4%of these patients,respectively,during HVPG measurement and by 54.6%32.5%,11.4%,1.5%,and 0%,respectively,after HVPG measurement.Of these patients,39.5%had little understanding and 10%had no understanding of the value of HVPG measurement,with 35.1%and 4.1%regarding HVPG measurements as being of little or no help,respectively.Most patients reported that they would definitely(15.5%),probably(46.9%),or possibly(29.9%)choose to undergo additional HVPG measurements again,and 62.7%regarded the cost of the procedure as acceptable.Conclusion:HVPG measurement was safe and well‐tolerated in patients with cirrhosis,but patient education and communication are warranted to improve the acceptance of this procedure.展开更多
Clinically significant portal hypertension(CSPH),defined as a hepatic venous pressure gradient(HVPG)≥10 mmHg,is an independent risk factor for decompensated events in patients with compensated cirrhosis.Currently,the...Clinically significant portal hypertension(CSPH),defined as a hepatic venous pressure gradient(HVPG)≥10 mmHg,is an independent risk factor for decompensated events in patients with compensated cirrhosis.Currently,the Baveno VII consensus recommends using nonselective beta-blockers to treat compensated cirrhosis in patients with CSPH.Here,we report a unusual case of compensated cirrhosis with CSPH caused by hepatitis B,and we successfully adjust NSBBs drug treatment strategies monitoring by HVPG results and achieve response standards.Timely adjustment of NSBBs drug treatment strategies based on HVPG test results for patients with CSPH can improve the final response rate.展开更多
Aims:Surveys and research on the applications of the hepatic venous pressure gradient(HVPG)are important for understanding the current status and future development of this technology in China.This article aimed to in...Aims:Surveys and research on the applications of the hepatic venous pressure gradient(HVPG)are important for understanding the current status and future development of this technology in China.This article aimed to investigate the status of hepatic venous pressure gradient measurement in China in 2022.Methods:We investigated the overall status of HVPG technology in China-including hospital distribution,hospital level,annual number of cases,catheters used,average cost,indications,and current challenges by using online questionnaire.By counting the number and percentages of cases of these results,we hope to clarify the current status of HVPG measurements in China.Results:According to the survey,85 hospitals in China used HVPG technology in 2022 distributed across 29 provinces.A total of 4989 HVPG measurements were performed in all of the surveyed hospitals in 2022,of which 2813 cases(56.4%)were measured alone.The average cost of HVPG measurement was 5646.8±2327.9 CNY.Of the clinical teams who performed the measurements(sometimes multiple per hospital),94.3%(82/87)used the balloon method,and the majority of the teams(72.4%,63/87)used embolectomy catheters.Conclusions:This survey clarified the clinical application status of HVPG in China and confirmed that some medical institutions in China have established a foundation for this technology.It is still necessary to continue promoting and popularizing this technology in the future.展开更多
基金supported by the Guangdong Basic and Applied Basic Research Foundation(2023A1515012784)Special Funds for Science and Technology Planning Project of Guangzhou(2023A04J1439)+1 种基金The Key Project of Department of Education of Guangdong Province(2020ZDZX1026)National Natural Science Foundation of China(31902409,31872606,31572657,U1701233).
文摘As the only molecule that can transport iron to the cell exterior,the ferroportin 1(FPN1)plays a key role in regulating the homeostasis of the iron ion.However,the function of FPN1 in teleost is remains unclear.In this study,the fpn1 gene was cloned from grass carp and its characteristics were studied.The results showed that grass carp Fpn1 protein contains eight transmembrane domains,which are similar to the amino acid sequences of different species.The tissue distribution of fpn1 was investigated by quantitative real-time PCR(qRT-PCR),which showed that the expression of fpn1 was the highest in the liver,followed by the spleen and muscle.Secondly,the haemolysis model of grass carp was established by the injection of phenylhydrazine(PHZ),and the effect of Fpn1 on the intestine in during haemolysis was explored.The determination data revealed that the PHZ-induced haemolysis increased the number of goblet cells in intestinal,as well as malondialdehyde(Mda),decreased glutathione peroxidase 4(Gpx4)content in foregut.The result of tissue immunofluorescence assay showed that the PHZ-induced haemolysis modulated the expression of iron metabolism related genes,including Fpn1 and Tfr1(transferrin receptor 1)in the intestine.Further determination data suggested that the iron deposition and apoptosis were higher in PHZ treatment group than that of the group.Taken together,the PHZ-induced haemolysis destroyed the iron homeostasis in intestinal and caused oxidative damage,the data of this study lays a foundation for the study of the mechanisms of intestinal iron homeostasis and provides a theoretical basis for understanding intestinal healthy.
基金Gansu Science Fund for Distinguished Young Scholars,Grant/Award Number:20JR10RA713Guangxi Digestive Disease Clinical Medical Research Center Construction Project,Grant/Award Number:AD17129027+7 种基金Tianjin Science and Technology Plan Project,Grant/Award Number:19ZXDBSY00030The Xingtai City Science and Technology Project,Grant/Award Number:2020ZZ026Zhejiang Provincial Natural Science Foundation of China,Grant/Award Number:LZ18H180001The Hebei Provincial Health and Family Planning Commission Scientific Research Fund Project,Grant/Award Number:20181612Wenzhou Municipal Science and Technology Bureau,Grant/Award Number:Y2020013National Natural Science Foundation of China,Grant/Award Numbers:81860654,81971713The Hebei Provincial Key R&D Program Project,Grant/Award Number:18277717DNatural Science Foundation of Science and Technology Department of Tibet Autonomous Region,Grant/Award Number:XZ2017ZRG‐91。
文摘Aim:To determine the tolerance and acceptance of hepatic venous pressure gradient(HVPG)measurements in patients with liver cirrhosis.Methods:This prospective international multicenter study included 271 patients with cirrhosis who were scheduled to undergo HVPG measurement between October 2019 and June 2020.Data related to the tolerance and acceptance of HVPG measurements were collected using descriptive questionnaires.Results:HVPG measurements were technically successful in all 271 patients,with 141(52.0%)undergoing HVPG measurement alone.The complication rate was 0.4%.Postoperative pain was significantly lower than preoperative expected pain(p<0.001)and intraoperative pain(p<0.001),and intraoperative pain was also significantly lower than preoperative expected pain(p=0.036).No,mild,moderate,severe,and intolerable discomfort scores were reported by 36.9%,44.6%,11.1%,6.3%,and 0.4%of these patients,respectively,during HVPG measurement and by 54.6%32.5%,11.4%,1.5%,and 0%,respectively,after HVPG measurement.Of these patients,39.5%had little understanding and 10%had no understanding of the value of HVPG measurement,with 35.1%and 4.1%regarding HVPG measurements as being of little or no help,respectively.Most patients reported that they would definitely(15.5%),probably(46.9%),or possibly(29.9%)choose to undergo additional HVPG measurements again,and 62.7%regarded the cost of the procedure as acceptable.Conclusion:HVPG measurement was safe and well‐tolerated in patients with cirrhosis,but patient education and communication are warranted to improve the acceptance of this procedure.
基金This study was conducted under the Declaration of Helsinki(revised in 2013).This study was approved by the Institutional Ethics Committee of the Taiyuan Third People's Hospital.
文摘Clinically significant portal hypertension(CSPH),defined as a hepatic venous pressure gradient(HVPG)≥10 mmHg,is an independent risk factor for decompensated events in patients with compensated cirrhosis.Currently,the Baveno VII consensus recommends using nonselective beta-blockers to treat compensated cirrhosis in patients with CSPH.Here,we report a unusual case of compensated cirrhosis with CSPH caused by hepatitis B,and we successfully adjust NSBBs drug treatment strategies monitoring by HVPG results and achieve response standards.Timely adjustment of NSBBs drug treatment strategies based on HVPG test results for patients with CSPH can improve the final response rate.
文摘Aims:Surveys and research on the applications of the hepatic venous pressure gradient(HVPG)are important for understanding the current status and future development of this technology in China.This article aimed to investigate the status of hepatic venous pressure gradient measurement in China in 2022.Methods:We investigated the overall status of HVPG technology in China-including hospital distribution,hospital level,annual number of cases,catheters used,average cost,indications,and current challenges by using online questionnaire.By counting the number and percentages of cases of these results,we hope to clarify the current status of HVPG measurements in China.Results:According to the survey,85 hospitals in China used HVPG technology in 2022 distributed across 29 provinces.A total of 4989 HVPG measurements were performed in all of the surveyed hospitals in 2022,of which 2813 cases(56.4%)were measured alone.The average cost of HVPG measurement was 5646.8±2327.9 CNY.Of the clinical teams who performed the measurements(sometimes multiple per hospital),94.3%(82/87)used the balloon method,and the majority of the teams(72.4%,63/87)used embolectomy catheters.Conclusions:This survey clarified the clinical application status of HVPG in China and confirmed that some medical institutions in China have established a foundation for this technology.It is still necessary to continue promoting and popularizing this technology in the future.
